perindopril (aceon) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Perindoprilat is a metabolite of perindopril. Perindopril is a long-acting angiotensin converting enzyme (ACE) inhibitor and it is used to treat high blood pressure, heart failure or stable coronary artery disease. Perindopril is designed to allow oral administration as perindoprilat is poorly absorbed from the gastrointestinal tract.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

Australia

$0.0476 - $0.3696

United States

$0.4798 - $0.5174
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( amlodipine (norvasc), perindopril (aceon) )

Alternative names

(2s,3as,7as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1h-indole-2-carboxylic acid | aceon | coversyl | mcn-a-2833 | mcn-a-2833-109 | peridopril | perindopril | perindopril arginine | perindopril erbumine | perindoprilum | perindropil | s-9490 | s-9490-3

Organizations (85)

Research & Development (77)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (9)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (39)

Approved Indications (3)


 

Coronary Artery Disease

Heart Failure

Hypertension

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Aging (Phase 2)

Albuminuria (Phase 3)

Alzheimer Disease (Phase 2)

Aortic Aneurysm, Abdominal (Phase 2)

Atrial Fibrillation (Phase 3)

Blood Pressure (Phase 4)

Breast Neoplasms (Phase 1/Phase 2)

Cancer Survivors (Phase 2)

Cardiomyopathy, Dilated (Phase 3)

Cardiovascular Diseases (Phase 3)

Cerebral Small Vessel Diseases (Phase 4)

Colorectal Neoplasms (Phase 2)

COVID-19 (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 2 (Phase 4)

Dyslipidemias (Phase 4)

Essential Hypertension (Phase 4)

Heart Diseases (Phase 4)

Heart Failure (Phase 4)

Hypercholesterolemia (Phase 4)

Hypertension (Phase 4)

Hyperuricemia (Phase 4)

Hypotension (Phase 4)

Lipid Metabolism Disorders (Phase 4)

Marfan Syndrome (Phase 4)

Menopause (Phase 4)

Metabolic Syndrome (Phase 4)

Methamphetamine (Phase 1)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Non-alcoholic Fatty Liver Disease (Phase 4)

Obesity (Phase 2)

Parkinson Disease ()

Proteinuria (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Sedentary Behavior (Phase 2)

Stress Disorders, Post-Traumatic (Phase 1)

Substance-Related Disorders (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 61
  • # of Trial Organizations: 77

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue